Business description
Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety.
Management board & Supervisory board
| CEO |
| Nachum Homi Shamir |
| Management board |
| Harriss T. Currie, Dr. Charles J. Collins, Eric S. Shapiro, Nancy M. Fairchild, Randall Myers, Richard Rew, Todd C. Bennet |
| Supervisory board |
| Nachum Homi Shamir, Dijuana K. Lewis, Dr. Edward A. Ogunro, Dr. Stephen L. Eck, Jim D. Kever, Kenneth A. Samet, Kevin M. McNamara, Thomas W. Erickson |
Company data
| Name: |
Luminex Corp. |
| Address: |
12212 Technology Blvd.,Austin, Texas 78727, USA |
| Phone: |
+1-512-219-8020 |
| Fax: |
+1-512-219-5195 |
| E-mail: |
-
|
| Internet: |
www.luminexcorp.com |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
61.80% |
| IPO date: |
- |
